- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05794958
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
July 13, 2023 updated by: Stanford University
A Phase Ib, Open Label Study to Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kelly Chyan, MPH
- Phone Number: (650) 725-8130
- Email: kchyan@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford University
-
Sub-Investigator:
- Wen-Kai Weng, MD, PhD
-
Sub-Investigator:
- Melody Smith, MD
-
Contact:
- Kelly Chyan, MPH
- Phone Number: 650-725-8130
- Email: kchyan@stanford.edu
-
Sub-Investigator:
- Lori Muffly, MD, MS
-
Sub-Investigator:
- Sally Arai, MD
-
Sub-Investigator:
- Laura Johnston, MD
-
Sub-Investigator:
- Robert Lowsky, MD
-
Sub-Investigator:
- Everett Meyer, MD, PhD
-
Sub-Investigator:
- Robert Negrin, MD
-
Sub-Investigator:
- Andrew Rezvani, MD
-
Sub-Investigator:
- Judith Shizuru, MD, PhD
-
Sub-Investigator:
- Praveen Shiraz, MD
-
Sub-Investigator:
- Matthew Frank, MD, PhD
-
Sub-Investigator:
- Surbhi Sidana, MD
-
Sub-Investigator:
- David B. Miklos, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Diagnosis: Histologically confirmed aggressive B cell NHL including the following types defined by WHO 2008:
- Diffuse large B cell lymphoma (DLBCL); OR
- primary mediastinal (thymic) large B cell lymphoma; OR
- transformation of follicular lymphoma (TFL), marginal zone lymphoma to DLBCL; OR
- high grade B-cell Lymphoma NOS will also be included
- Patients must be considered high-risk lymphoma (defined as LDH greater than upper limit of normal per institutional cut-off) at or within two weeks of leukapheresis.
- Subjects must have received at least and a maximum one prior line of therapy for LBCL indication (i.e subjects receiving second line standard of care Axi-Cel will be enrolled in this study).
- At least 1 measurable lesion on PET-CT or CT scan. If the only measurable disease is lymph-node disease, at least 1 lymph node should be ≥ 1.5 cm.
- Age 18 years or older
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1. ECOG 2 permitted if performance status is solely attributed to lymphoma.
Normal Organ and Marrow Function
- ANC ≥ 1,000/uL
- Platelet count ≥ 75,000/uL
Adequate renal, hepatic, pulmonary and cardiac function defined as:
- Creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min
- Serum ALT or AST ≤ 2.5 x ULN (except in subjects with liver involvement by lymphoma)
- Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome.
- Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an Echocardiogram.
- No clinically significant pleural effusion or ascites
- Baseline oxygen saturation > 92% on room air
- Ability to understand and the willingness to sign the written IRB-approved informed consent document. Subjects unable to give informed consent will not be eligible for this study.
- Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
- Contraception: Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for twelve (12) months after receiving the preparative lymphodepletion regimen.
- If prior CD19 directed therapy, demonstrates CD19 positivity by biopsy (Flow cytometry or immunohistochemistry per the institutional criteria)
Exclusion Criteria:
- Prior treatment with CAR-T or adoptive cell therapy.
- Prior allogeneic transplant.
- No bridging therapy permitted except for steroids or radiotherapy (bridging therapy with steroids e.g. dexamethasone 40 mg for 5 days or radiotherapy is permitted). Measurable non-irradiated lesion post-apheresis needed for enrollment.
- Active central nervous system disease from lymphoma. MRI of the brain with no evidence of CNS lymphoma if prior history of CNS involvement.
- Prior history of allergic reactions or severe infusion reaction to Axi-Cel or any of the reagents used in the Axi-Cel infusion.
- History of Richter's transformation of chronic leukemic lymphoma, small lymphocytic lymphoma, or lymphoplasmacytic lymphoma.
- Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment.
- Women who are pregnant or breastfeeding
History of invasive malignancy unless the patient has been disease-free for five years.
- Exception: Nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, and breast) is eligible.
- Hormonal therapy in subjects in remission >1 year will be allowed.
- History of stroke or transient ischemic attack within 12 months before enrollment, or seizure disorders requiring active anticonvulsive medication.
- In the investigator's judgment, the subject is unlikely to complete all study specific visits or procedures, including follow-up visits, or comply with the study requirements for participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Safety Run-in phase
First three patients (maximum of 6) will receive 0.5 x 106/kg CART cells (25% standard dose) as reinfusion product between days 7 through 14 if CRS/ICANS has resolved to a grade 1 or less.
|
Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
Other Names:
|
Experimental: Phase 1b
Up to 20 evaluable subjects will receive the target dose of AxiCel infusion to evaluate efficacy of Axi-Cel-2 in adults with high risk relapsed/refractory LBCL
|
Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of toxicities,dose limiting toxicity (DLT) of a second dose of AxiCel (Axi-Cel2) in adults with relapsed/refractory high-risk LBCL.
Time Frame: 28 days
|
Subjects will be assessment for dose limiting toxicity (DLT) for 28 days after the infusion of Axi-Cel-2
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free survival (PFS)
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Saurabh Dahiya, MD, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 23, 2023
Primary Completion (Estimated)
April 1, 2038
Study Completion (Estimated)
April 1, 2038
Study Registration Dates
First Submitted
March 20, 2023
First Submitted That Met QC Criteria
March 20, 2023
First Posted (Actual)
April 3, 2023
Study Record Updates
Last Update Posted (Actual)
July 17, 2023
Last Update Submitted That Met QC Criteria
July 13, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-68723
- CCT5068 (Other Identifier: OnCore)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin Lymphoma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on Axicabtagene Ciloleucel
-
The Lymphoma Academic Research OrganisationActive, not recruitingB-cell Lymphoma Recurrent | B-Cell Lymphoma RefractoryFrance, Belgium
-
Kite, A Gilead CompanyAvailableFollicular Lymphoma | Large B-cell LymphomaUnited States, Japan
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Marcela V. Maus, M.D.,Ph.D.Kite, A Gilead CompanyActive, not recruitingNon Hodgkin Lymphoma | Neurotoxicity | Neurotoxicity Syndromes | Cytokine Release Syndrome | Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin LymphomaUnited States
-
Incyte CorporationCompletedCytokine Release SyndromeUnited States
-
Kite, A Gilead CompanyEnrolling by invitationSolid and Hematological MalignanciesUnited States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
-
Kite, A Gilead CompanyCompletedB-cell LymphomaUnited States, Australia, France
-
Kite, A Gilead CompanyActive, not recruitingFollicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-Hodgkin LymphomaUnited States, France
-
Kite, A Gilead CompanyCompletedRelapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)United States, Netherlands, Canada, France, Germany, Israel
-
Dana-Farber Cancer InstituteKite, A Gilead CompanyActive, not recruiting